Home > Haematology > ASH 2019 > Inclusive Medicine > Oral selinexor/pomalidomide/dexamethasone shows activity in heavily pre-treated multiple myeloma

Oral selinexor/pomalidomide/dexamethasone shows activity in heavily pre-treated multiple myeloma

Presented By
Dr Christine Chen, Princess Margaret Cancer Centre, University of Toronto, Canada
Conference
ASH 2019
Trial
MM-003, STOMP
Dr Christine Chen (Princess Margaret Cancer Centre, University of Toronto, Canada) presented the results of 51 heavily pre-treated multiple myeloma (MM) patients in an open-label, dose escalation (phase 1) and expansion (phase 2) study evaluating selinexor in combination with pomalidomide and low-dose dexamethasone. Although the numbers were small, the investigators observed a manageable safety profile of this triple oral combination, a robust overall response rate, and determined a dose and scheduling regimen for the phase 2 follow-up of this study [1]. Selinexor is an oral selective XPO1 inhibitor. XPO (exportin-1, the major nuclear exporter for tumour suppressor proteins, the glucocorticoid receptor, and elF4E-bound oncoprotein mRNAs such as c-Myc, Bcl, MDM2, and cyclins) is overexpressed in MM. In vitro and in vivo data demonstrate that selinexor reactivates tumour suppressor pathways and glucocorticoid receptor signalling in MM model...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on